CRBU insider transaction filings
Caribou Biosciences, Inc. — 29 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-02-27. Screen CRBU transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-02-27 | 4 | Kelly Timothy P — Chief Technology Officer | Sale (S): 6,228 @ $1.93 | EDGAR |
| 2026-02-24 | 4 | Albertson Tina M. — Chief Medical Officer | Grant/award (A): 55,000 @ $0 · Sale (S): 1,066 @ $1.96 · Grant/award (A): 247,500 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | Khan Ruhi Ahmad — Chief Business Officer | Grant/award (A): 45,000 @ $0 · Sale (S): 6,938 @ $1.96 · Grant/award (A): 202,500 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | Kelly Timothy P — Chief Technology Officer | Grant/award (A): 45,000 @ $0 · Sale (S): 3,147 @ $1.96 · Grant/award (A): 202,500 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | MCCLUNG BARBARA G — Chief Legal Officer | Grant/award (A): 45,000 @ $0 · Sale (S): 6,938 @ $1.96 · Grant/award (A): 202,500 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Richardson-Heron Dara — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Zheng Ran — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Whiting Nancy — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Ryali Sriram — Chief Financial Officer | Grant/award (A): 55,000 @ $0 · Grant/award (A): 247,500 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | JOHNSON DAVID LEE — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Sacks Natalie — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Haurwitz Rachel E. — President and CEO, Director | Grant/award (A): 151,700 @ $0 · Grant/award (A): 682,500 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Braunstein Scott — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | GUGGENHIME ANDREW — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-03-17 | 4 | Haurwitz Rachel E. — President and CEO, Director | Purchase (P): 20,000 @ $1.02 | EDGAR |
| 2025-02-21 | 4 | Albertson Tina M. — Chief Medical Officer | Grant/award (A): 14,589 @ $0 · Grant/award (A): 66,137 (derivative) @ $0 | EDGAR |
| 2025-02-21 | 4 | Richardson-Heron Dara — Director | Grant/award (A): 40,500 (derivative) @ $0 | EDGAR |
| 2025-02-21 | 4 | Khan Ruhi Ahmad — Chief Business Officer | Grant/award (A): 37,500 @ $0 · Sale (S): 3,564 @ $1.35 · Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2025-02-21 | 4 | Zheng Ran — Director | Grant/award (A): 40,500 (derivative) @ $0 | EDGAR |
| 2025-02-21 | 4 | Whiting Nancy — Director | Grant/award (A): 40,500 (derivative) @ $0 | EDGAR |
| 2025-02-21 | 4 | Kanner Steven — Chief Scientific Officer | Grant/award (A): 37,500 @ $0 · Sale (S): 3,564 @ $1.35 · Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2025-02-21 | 4 | Kelly Timothy P — Chief Technology Officer | Grant/award (A): 37,500 @ $0 · Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2025-02-21 | 4 | JOHNSON DAVID LEE — Director | Grant/award (A): 40,500 (derivative) @ $0 | EDGAR |
| 2025-02-21 | 4 | Sacks Natalie — Director | Grant/award (A): 40,500 (derivative) @ $0 | EDGAR |
| 2025-02-21 | 4 | Haurwitz Rachel E. — President and CEO, Director | Grant/award (A): 136,750 @ $0 · Grant/award (A): 618,250 (derivative) @ $0 | EDGAR |
| 2025-02-21 | 4 | Braunstein Scott — Director | Grant/award (A): 40,500 (derivative) @ $0 | EDGAR |
| 2025-02-21 | 4 | MCCLUNG BARBARA G — Chief Legal Officer | Grant/award (A): 37,500 @ $0 · Sale (S): 3,564 @ $1.35 · Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2025-02-21 | 4 | GUGGENHIME ANDREW — Director | Grant/award (A): 40,500 (derivative) @ $0 | EDGAR |
| 2025-01-30 | 4 | Ryali Sriram — Chief Financial Officer | Purchase (P): 17,360 @ $1.42 | EDGAR |
Recent 8-K events — Caribou Biosciences, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-11 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-31 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-03 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-23 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CRBU returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →